"Off-Label Use" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The practice of prescribing or using a drug outside the scope of the drug's official approved label as designated by a regulatory agency concerning the treatment of a particular disease or condition.
| Descriptor ID |
D056687
|
| MeSH Number(s) |
E02.319.307.500
|
| Concept/Terms |
Off-Label Use- Off-Label Use
- Off Label Use
- Off-Label Uses
- Use, Off-Label
- Uses, Off-Label
- Off-Label Prescribing
- Off Label Prescribing
- Off-Label Prescribings
- Prescribing, Off-Label
- Prescribings, Off-Label
- Unlabeled Indication
- Indication, Unlabeled
- Indications, Unlabeled
- Unlabeled Indications
|
Below are MeSH descriptors whose meaning is more general than "Off-Label Use".
Below are MeSH descriptors whose meaning is more specific than "Off-Label Use".
This graph shows the total number of publications written about "Off-Label Use" by people in this website by year, and whether "Off-Label Use" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Off-Label Use" by people in Profiles.
-
Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard. J Clin Endocrinol Metab. 2021 06 16; 106(7):2103-2113.
-
Postmarket Experience of Polymethylmethacrylate-Collagen Gel Dermal Filler. Dermatol Surg. 2020 08; 46(8):1086-1091.
-
A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA Intern Med. 2019 05 01; 179(5):695-701.
-
Thalidomide, Drug Safety, and Off-label Prescribing: Lessons Learned From Celgene's Settlement. JAMA Oncol. 2018 07 01; 4(7):915-916.
-
Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern? N Engl J Med. 2017 Aug 03; 377(5):411-414.
-
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. J Immunother Cancer. 2017 07 18; 5(1):58.
-
The relevance of research study phase to disclosure of off-label drug availability. Am J Bioeth. 2014; 14(4):53-4.
-
Controversies in the use of second generation antipsychotics as sleep agent. Pharmacol Res. 2014 Jan; 79:1-8.
-
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract. 2012 Nov; 8(6):e158-67.
-
Enforcement actions involving Medicaid fraud and abuse, 1996-2009. Arch Intern Med. 2011 Apr 25; 171(8):785-7.